Drug · DIN 02560569
FEMYSO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 3, 2026; first marketed February 3, 2026.
- Drug Identification Number (DIN)
- 02560569
- Company (DIN owner)
- Lupin Pharma Canada LimitedLongueuil, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Kit; Tablet
- Route
- Buccal; Oral
- Therapeutic class (ATC)
- Mifepristone, combinations G03XB51
- Class
- Human
- Record last updated
- February 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MIFEPRISTONE | 200 MG | |
| MISOPROSTOL | 200 MCG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 26, 2025: NOC 35907Abbreviated New Drug Submission (ANDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “femyso”. A notice may cover another product or only some lots: read it to see what it covers.
- Femyso: Affected lot may contain two green Mifepristone cartons or two pink Misoprostol cartons instead of one of each.July 30, 2026 · Drugs · Packaging · Type II